For women who choose nonhormonal therapy for hot flashes, fezolinetant appears to be one of several modestly efficacious and safe options — but women want more.
References
Dominus, S. The New York Times Magazine https://go.nature.com/44DMJmp (1 February 2023).
Rep. McKinley, D. B. [R-W.-1. H.R.8774 – 117th Congress (2021–2022): Menopause Research Act of 2022 (2022).
Lederman, S. et al. Lancet 401, 1091–1102 (2023).
Williams, R. E. et al. Climacteric J. Int. Menopause Soc. 11, 32–43 (2008).
Nappi, R. E. et al. Maturitas 167, 66–74 (2023).
Joffe, H. et al. JAMA Intern. Med. 174, 1058–1066 (2014).
Freeman, E. W. et al. JAMA 305, 267–274 (2011).
Beaudoin, F. L. et al. https://go.nature.com/3NUjcir (ICER, 2023).
Johnson, K. A. et al. J. Clin. Endocrinol. Metab. https://doi.org/10.1210/clinem/dgad058 (2023).
Grand View Research. https://go.nature.com/3VKXHm3 (Cision PR Newswire, 2022).
Davis, S. R. et al. Nat. Rev. Dis. Primer 1, 15004 (2015).
Author information
Authors and Affiliations
Corresponding authors
Ethics declarations
Competing interests
The authors declare no competing interests.
Rights and permissions
About this article
Cite this article
LaCroix, A., Ensrud, K. The flash dance of midlife: the Skylight 1 trial. Nat Med 29, 1324–1325 (2023). https://doi.org/10.1038/s41591-023-02359-8
Published:
Issue Date:
DOI: https://doi.org/10.1038/s41591-023-02359-8
- Springer Nature America, Inc.